AVAL vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 0/9, indicating severe deterioration in fundamental performance. Despite strong recent price momentum and solid earnings growth, the company exhibits alarming profitability distortions—operating and gross margins are 0.00%, while the Price/Book ratio of 0.01 suggests either a deep-value opportunity or potential accounting irregularities. Revenue and earnings growth are impressive, but inconsistent earnings surprises and a lack of transparency in balance sheet metrics (missing debt, cash, and Altman Z-Score) undermine confidence. The stock trades above the conservative Graham Number of $80.35, but this appears to be a data error given the current price of $4.68, suggesting possible misreporting or unit discrepancy.
JPM shows bullish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Key strengths include strong valuation and growth metrics. Price trades at a 109.8% premium to fair value estimate ($140.21), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
AVAL vs JPM: Head-to-Head Comparison
This page compares Grupo Aval Acciones y Valores S.A. (AVAL) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.